Session » Vasculitis IV: Diagnosis and Assessment of Disease Activity

Date: Wednesday, November 16, 2016

Time: 9:00AM-10:30AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-10:30AM: Abstract Number: 3184

Antiphospoholipid Antibodies in Giant Cell Arteritis. What Can They Tell Us?

9:00AM-10:30AM: Abstract Number: 3182

Attenuation of Fluorine-18-Fluorodeoxyglucose Uptake in Large Vessel Giant Cell Arteritis after Short-Term High-Dose Steroid Treatment – a Diagnostic Window of Opportunity

9:00AM-10:30AM: Abstract Number: 3179

Scale Structure and Measurement Properties of a Disease Specific Patient-Reported Outcome for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

9:00AM-10:30AM: Abstract Number: 3181

The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis

9:00AM-10:30AM: Abstract Number: 3183

Tocilizumab for the Treatment of Giant Cell Arteritis – MR-Angiography Results from the First Randomized Placebo-Controlled Trial

9:00AM-10:30AM: Abstract Number: 3180

Utility of Measurements of Urinary Soluble CD163 & MCP-1 in the Identification of Subtle Renal Flares in ANCA-Associated Vasculitis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].